444 related articles for article (PubMed ID: 34822719)
1. Novel drug developmental strategies for treatment-resistant depression.
Borbély É; Simon M; Fuchs E; Wiborg O; Czéh B; Helyes Z
Br J Pharmacol; 2022 Mar; 179(6):1146-1186. PubMed ID: 34822719
[TBL] [Abstract][Full Text] [Related]
2. Ketamine for Treatment-Resistant Depression: a New Advocate.
Pérez-Esparza R
Rev Invest Clin; 2018; 70(2):65-7. PubMed ID: 29718013
[TBL] [Abstract][Full Text] [Related]
3. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
[TBL] [Abstract][Full Text] [Related]
4. Next generation antidepressants with novel mechanisms for treatment resistant depression.
Chen MH; Tu PC; Su TP
Prog Brain Res; 2023; 278():149-168. PubMed ID: 37414491
[TBL] [Abstract][Full Text] [Related]
5. The promise of ketamine for treatment-resistant depression: current evidence and future directions.
DeWilde KE; Levitch CF; Murrough JW; Mathew SJ; Iosifescu DV
Ann N Y Acad Sci; 2015 May; 1345(1):47-58. PubMed ID: 25649308
[TBL] [Abstract][Full Text] [Related]
6. Nitrous Oxide: an emerging novel treatment for treatment-resistant depression.
Quach DF; de Leon VC; Conway CR
J Neurol Sci; 2022 Mar; 434():120092. PubMed ID: 34953347
[TBL] [Abstract][Full Text] [Related]
7. Keeping up with the clinical advances: depression.
Ragguett RM; Tamura JK; McIntyre RS
CNS Spectr; 2019 Aug; 24(S1):25-37. PubMed ID: 31248466
[TBL] [Abstract][Full Text] [Related]
8. Ketamine for depression.
Jelen LA; Stone JM
Int Rev Psychiatry; 2021 May; 33(3):207-228. PubMed ID: 33569971
[TBL] [Abstract][Full Text] [Related]
9. Preclinical models of treatment-resistant depression: challenges and perspectives.
Kolasa M; Faron-Górecka A
Pharmacol Rep; 2023 Dec; 75(6):1326-1340. PubMed ID: 37882914
[TBL] [Abstract][Full Text] [Related]
10. Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review.
Rosenblat JD; McIntyre RS; Alves GS; Fountoulakis KN; Carvalho AF
Curr Neuropharmacol; 2015; 13(5):636-55. PubMed ID: 26467412
[TBL] [Abstract][Full Text] [Related]
11. Role of copper and ketamine in major depressive disorder - an update.
Słupski J; Słupska A; Szałach ŁP; Włodarczyk A; Górska N; Szarmach J; Jakuszkowiak-Wojten K; Gałuszko-Węgielnik M; Wilkowska A; Wiglusz MS; Cubała WJ
Psychiatr Danub; 2019 Sep; 31(Suppl 3):520-523. PubMed ID: 31488784
[TBL] [Abstract][Full Text] [Related]
12. Is the mGlu5 receptor a possible target for new antidepressant drugs?
Pałucha-Poniewiera A; Wierońska JM; Brański P; Burnat G; Chruścicka B; Pilc A
Pharmacol Rep; 2013; 65(6):1506-11. PubMed ID: 24552998
[TBL] [Abstract][Full Text] [Related]
13. Ketamine for treatment-resistant unipolar depression: current evidence.
Mathew SJ; Shah A; Lapidus K; Clark C; Jarun N; Ostermeyer B; Murrough JW
CNS Drugs; 2012 Mar; 26(3):189-204. PubMed ID: 22303887
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Strategies for Treatment-resistant Depression: State of the Art and Future Perspectives.
Goh KK; Chang SC; Chen CH; Lu ML
Curr Pharm Des; 2020; 26(2):244-252. PubMed ID: 31924151
[TBL] [Abstract][Full Text] [Related]
15. Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.
Kokane SS; Armant RJ; Bolaños-Guzmán CA; Perrotti LI
Behav Brain Res; 2020 Apr; 384():112548. PubMed ID: 32061748
[TBL] [Abstract][Full Text] [Related]
16. Ketamine: Leading us into the future for development of antidepressants.
Carreno FR; Lodge DJ; Frazer A
Behav Brain Res; 2020 Apr; 383():112532. PubMed ID: 32023492
[TBL] [Abstract][Full Text] [Related]
17. Crosstalk Between Inflammation and Glutamate System in Depression: Signaling Pathway and Molecular Biomarkers for Ketamine's Antidepressant Effect.
Cui W; Ning Y; Hong W; Wang J; Liu Z; Li MD
Mol Neurobiol; 2019 May; 56(5):3484-3500. PubMed ID: 30140973
[TBL] [Abstract][Full Text] [Related]
18. New Treatment Strategies of Depression: Based on Mechanisms Related to Neuroplasticity.
Huang YJ; Lane HY; Lin CH
Neural Plast; 2017; 2017():4605971. PubMed ID: 28491480
[TBL] [Abstract][Full Text] [Related]
19. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Murrough JW; Iosifescu DV; Chang LC; Al Jurdi RK; Green CE; Perez AM; Iqbal S; Pillemer S; Foulkes A; Shah A; Charney DS; Mathew SJ
Am J Psychiatry; 2013 Oct; 170(10):1134-42. PubMed ID: 23982301
[TBL] [Abstract][Full Text] [Related]
20. Novel approaches for the management of depressive disorders.
Kaster MP; Moretti M; Cunha MP; Rodrigues AL
Eur J Pharmacol; 2016 Jan; 771():236-40. PubMed ID: 26703867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
